Loading the company…
Loading the company…
㈜한국피엠지제약
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gyeonggi, founded in 2005. Industry: Bio & Pharma. Revenue for 2025 was ₩72.8bn. It has 107 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2019-10-08 · latest registration 2020-05-26 · newest first
본 발명은 모과, 우슬, 오가피, 육계, 진교, 위령선, 당귀, 천궁, 천마, 홍화, 속단 및 방풍으로 이루어진 생약 추출물; 및 세레콕시브 또는 이의 제약상 허용되는 염을 포함하는 염증 질환의 예방 또는 치료용 약학 조성물에 관한 것이다.
본 발명의 목적은, 목과, 홍화, 당귀, 방풍, 오가피 및 천궁을 필수적으로 포함하는 복합 생약 추출물 및 이로부터의 분획물을 포함하는 약학 조성물을 제조함으로써, 염증 반응 관련 인자들을 억제함에 따라 관절염을 포함하는 염증성 질환에 대한 예방 또는 치료에 활용할 수 있는 약학 조성물을 제공하고자 함에 있다. 상기와 같은 본 발명에 따르면, 상기 복합 생약 추출물 또는 분획물을 포함하는 약학 조성물을 제조함으로써, 염증성 사이토카인을 농도의존적으로 감소시키고 염증반응의 주요 전사인자들을 전좌 및 인산화 저해시킴에 따라 염증반응을 억제하는 효과가 있다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 70.6 | 72.8 |
| Cost of sales | 33.2 | 34.9 |
| Gross profit (loss) | 37.4 | 37.9 |
| Selling, general and administrative expenses | 33.4 | 32.6 |
| Operating income (loss) | 4.0 | 5.4 |
| Non-operating income | 1.0 | 0.8 |
| Other gains | 0.0 | 0.2 |
| Finance income | 0.7 | 0.7 |
| Other | 0.3 | — |
| Non-operating expenses | 1.7 | 0.7 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 1.0 | 0.6 |
| Other | 0.7 | 0.1 |
| Profit (loss) before tax | 3.3 | 5.5 |
| Income tax expense | 1.8 | 1.2 |
| Net income (loss) | 1.5 | 4.3 |
Revenue ₩72.8bn, up 3.1% YoY.
Operating margin 7.4% (prior 5.7%).
Net income ₩4.3bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-05